1. ‘Mobile Application for Anti-Doping’ containing more than 40,000 pharmaceuticals which allows athletes to check whether the pharmaceuticals are prohibited in-out-of-competition simply via typing in the product names. 2. ‘Gastroenteritis Defender’ utilizes nanotechnology to enhance andrographolide oral bioavailabilitycould effectively prevent gastrointestinal inflammatory disorders.

The bioactive corecorona synergism of sub-nanometer gold enables slowed inflammationincreased tissue regeneration in wound hypoxia. The developed dual-function wound dressing based on a gold nanocluster with a plane structurean adhesive layer presented two features: (1) the gold nanocluster can attenuate the inflammatory response by adjusting the strength of the active site (i.e., l

We developed a biomimetic triple-antibody-immobilized magnetic fucoidan nanomedicine as a multifunctional artificial antigen presenting cell, which possessed the ability to not only inhibit immune checkpoint but activate tumor infiltrated T cells. of Bridging sites with tunable density on the nanoplatform was designed, allowing the antibodies to be well-distributed on the surface for mimicking immune cells. In contrast to the complex cell expansion process using microbeads in adaptive cell therapy, the nanoplatform can be i.v. administrated to cut the course of therapy from several weeks to days. With the development of the platform technology, an artificial immune system family can be built to pave the way for personalized immunotherapy.

SeraParma™ COVID-19 IgM rapid test has high detection sensitivity, which can provide rapid detection of early COVID-19 infection. This SeraParma™ COVID-19 IgM rapid test can detect whether there are IgM antibodies produced in the early stage of infection (within 7 days of symptoms onset) with one drop of the specimen (serumfingertip blood) in 15 minutes by naked eyes compared with LFIA antibody rapid test. It is worth noting that the SeraParma™ COVID-19 IgM rapid test can accurately detect the patients with positive infection within 7 days of the onset of symptoms compared with LFIA.